S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Urgent Warning (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The "King Of Quants" sees 10X potential... (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Urgent Warning (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The "King Of Quants" sees 10X potential... (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Urgent Warning (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The "King Of Quants" sees 10X potential... (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Urgent Warning (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The "King Of Quants" sees 10X potential... (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
NASDAQ:LTRN

Lantern Pharma - LTRN Stock Forecast, Price & News

$4.58
+0.07 (+1.55%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.55
▼
$4.65
50-Day Range
$4.30
▼
$6.08
52-Week Range
$4.05
▼
$7.92
Volume
9,652 shs
Average Volume
36,620 shs
Market Capitalization
$49.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Lantern Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
140.2% Upside
$11.00 Price Target
Short Interest
Healthy
2.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of Lantern Pharma in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.54) to ($2.42) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

439th out of 995 stocks

Pharmaceutical Preparations Industry

203rd out of 482 stocks

See Top Rated MarketRank™ Stocks Here

LTRN stock logo

About Lantern Pharma (NASDAQ:LTRN) Stock

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

LTRN Stock News Headlines

March 24, 2023 | finance.yahoo.com
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2022 Earnings Call Transcript
March 23, 2023 | americanbankingnews.com
Lantern Pharma (NASDAQ:LTRN) Rating Reiterated by EF Hutton Acquisition Co. I
March 28, 2023 | Investor Place Media (Ad)
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
March 22, 2023 | benzinga.com
Lantern Pharma Stock (NASDAQ:LTRN), Guidance and Forecast
March 22, 2023 | americanbankingnews.com
Lantern Pharma (NASDAQ:LTRN) Posts Earnings Results, Beats Expectations By $0.18 EPS
March 21, 2023 | finance.yahoo.com
Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars
March 21, 2023 | markets.businessinsider.com
EF Hutton Reaffirms Their Buy Rating on Lantern Pharma (LTRN)
March 21, 2023 | finance.yahoo.com
Q4 2022 Lantern Pharma Inc Earnings Call
March 28, 2023 | Investor Place Media (Ad)
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
March 20, 2023 | finance.yahoo.com
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
March 19, 2023 | americanbankingnews.com
Lantern Pharma (LTRN) Scheduled to Post Earnings on Monday
March 17, 2023 | benzinga.com
Lantern Pharma's Earnings: A Preview
March 15, 2023 | finance.yahoo.com
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
March 13, 2023 | finance.yahoo.com
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
March 9, 2023 | finance.yahoo.com
Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors
March 8, 2023 | finance.yahoo.com
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
March 6, 2023 | msn.com
Lantern forms unit Starlight focused on CNS disorders, brain cancers
March 6, 2023 | finance.yahoo.com
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
March 2, 2023 | finance.yahoo.com
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials
March 1, 2023 | benzinga.com
Lantern Pharma Stock (NASDAQ:LTRN), Quotes and News Summary
February 27, 2023 | finance.yahoo.com
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
February 17, 2023 | benzinga.com
EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target
February 15, 2023 | finance.yahoo.com
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
February 1, 2023 | finance.yahoo.com
LTRN: LP-184 & LP-284 in the Spotlight
January 28, 2023 | msn.com
A Passion for Lifelong Learning is Part of the Culture of Lantern Hill
January 17, 2023 | finance.yahoo.com
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
January 5, 2023 | finance.yahoo.com
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma
See More Headlines
Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

LTRN Company Calendar

Last Earnings
3/20/2023
Today
3/27/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LTRN
CUSIP
N/A
CIK
1763950
Web
www.lanternpharma.com
Phone
972-277-1136
Fax
N/A
Employees
14
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+139.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,360,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-23.62%
Return on Assets
-22.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
20.99
Quick Ratio
19.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.40 per share
Price / Book
0.72

Miscellaneous

Outstanding Shares
10,860,000
Free Float
8,360,000
Market Cap
$49.96 million
Optionable
Not Optionable
Beta
0.68

Social Links


Key Executives

  • Mr. Panna Sharma PH.D. (Age 51)
    Pres, CEO & Director
    Comp: $622k
  • Mr. David R. Margrave (Age 61)
    CFO & Sec.
    Comp: $366k
  • Dr. Kishor Gopaldas Bhatia Ph.D. (Age 67)
    Chief Scientific Officer & Scientific Consultant
    Comp: $151.93k
  • Nicole Leber
    Investor Relations Associate, Fin. & Admin. Coordinator
  • Dr. Peter L. Nara D.V.M.
    M.S., Ph.D., Co-Founder & Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













LTRN Stock - Frequently Asked Questions

Should I buy or sell Lantern Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LTRN shares.
View LTRN analyst ratings or view top-rated stocks.

What is Lantern Pharma's stock price forecast for 2023?

1 brokerages have issued 1-year price targets for Lantern Pharma's stock. Their LTRN share price forecasts range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 139.1% from the stock's current price.
View analysts price targets for LTRN or view top-rated stocks among Wall Street analysts.

How have LTRN shares performed in 2023?

Lantern Pharma's stock was trading at $6.04 at the start of the year. Since then, LTRN shares have decreased by 23.8% and is now trading at $4.60.
View the best growth stocks for 2023 here.

When is Lantern Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our LTRN earnings forecast.

How were Lantern Pharma's earnings last quarter?

Lantern Pharma Inc. (NASDAQ:LTRN) issued its quarterly earnings results on Monday, March, 20th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.18. During the same quarter in the previous year, the company earned ($0.31) earnings per share.

What other stocks do shareholders of Lantern Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), First Trust NASDAQ 100 Equal Weighted Index Fund (QQEW), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK).

When did Lantern Pharma IPO?

(LTRN) raised $26 million in an initial public offering (IPO) on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

What is Lantern Pharma's stock symbol?

Lantern Pharma trades on the NASDAQ under the ticker symbol "LTRN."

Who are Lantern Pharma's major shareholders?

Lantern Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include CM Management LLC (0.55%), Wolff Wiese Magana LLC (0.25%), Jane Street Group LLC (0.14%), UBS Group AG (0.14%), Lynwood Capital Management Inc. (0.11%) and Susquehanna International Group LLP (0.00%).
View institutional ownership trends.

How do I buy shares of Lantern Pharma?

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantern Pharma's stock price today?

One share of LTRN stock can currently be purchased for approximately $4.60.

How much money does Lantern Pharma make?

Lantern Pharma (NASDAQ:LTRN) has a market capitalization of $49.96 million. The company earns $-12,360,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

How can I contact Lantern Pharma?

Lantern Pharma's mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The official website for the company is www.lanternpharma.com. The company can be reached via phone at 972-277-1136 or via email at info@lanternpharma.com.

This page (NASDAQ:LTRN) was last updated on 3/28/2023 by MarketBeat.com Staff